EUVIMEDEUVIMED entdecken
Crossref

Comparison of Addition of Indications for Antineoplastic Agents Approved in the United States and Japan from 2001 to 2020

Toshiyuki Shizuya, Seiko Miyazaki

Biological and Pharmaceutical Bulletin · 2023

DOI: 10.1248/bpb.b23-00149 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2023. Verfasst von Toshiyuki Shizuya und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Social Pharmacy and Regulatory Science, Showa Pharmaceutical University. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsHumansUnited StatesDrug ApprovalJapanUnited States Food and Drug Administration

Stichwörter der Autor:innen

JapanUnited Statesantineoplastic agentcancerindicationnew drug

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Division of Social Pharmacy and Regulatory Science, Showa Pharmaceutical University.
  • Japan Development, MSD K.K.

Zitieren

APA

Shizuya, T., & Miyazaki, S. (2023). Comparison of Addition of Indications for Antineoplastic Agents Approved in the United States and Japan from 2001 to 2020. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b23-00149

Vancouver

Shizuya T, Miyazaki S. Comparison of Addition of Indications for Antineoplastic Agents Approved in the United States and Japan from 2001 to 2020. Biological and Pharmaceutical Bulletin. 2023. doi:10.1248/bpb.b23-00149

BibTeX
@article{Shizuya2023,
  author = {Shizuya, Toshiyuki and Miyazaki, Seiko},
  title = {Comparison of Addition of Indications for Antineoplastic Agents Approved in the United States and Japan from 2001 to 2020},
  journal = {Biological and Pharmaceutical Bulletin},
  year = {2023},
  doi = {10.1248/bpb.b23-00149}
}
Kostenlos starten →